Vaccine biotechnology company Novavax (NASDAQ: NVAX) will be reporting results this Wednesday before market open. Here’s what you need to know.
Novavax beat analysts’ revenue expectations last quarter, reporting revenues of $147.1 million, up 66.6% year on year. It was an incredible quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ revenue estimates.
Is Novavax a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Novavax’s revenue to decline 88.7% year on year, a reversal from the 610% increase it recorded in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Novavax has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Novavax’s peers in the therapeutics segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Moderna delivered year-on-year revenue growth of 260%, beating analysts’ expectations by 55.8%, and Biogen reported revenues up 1.9%, topping estimates by 11.2%. Moderna traded up 2.6% following the results while Biogen was also up 3.2%.
Read our full analysis of Moderna’s results here and Biogen’s results here.
There has been positive sentiment among investors in the therapeutics segment, with share prices up 5.7% on average over the last month. Novavax is up 1.6% during the same time and is heading into earnings with an average analyst price target of $14.00 (compared to the current share price of $8.09).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
